Context-TAP: Tracking Any Point Demands Spatial Context Features

We tackle the problem of Tracking Any Point (TAP) in videos, which specifically aims at estimating persistent long-term trajectories of query points in videos. Previous methods attempted to estimate these trajectories independently to incorporate longer image sequences, therefore, ignoring the potential benefits of incorporating spatial context features. We argue that independent video point tracking also demands spatial context features. To this end, we propose a novel framework Context-TAP, which effectively improves point trajectory accuracy by aggregating spatial context features in videos. Context-TAP contains two main modules: 1) a SOurse Feature Enhancement (SOFE) module, and 2) a TArget Feature Aggregation (TAFA) module. Context-TAP significantly improves PIPs all-sided, reducing 11.4% Average Trajectory Error of Occluded Points (ATE-Occ) on CroHD and increasing 11.8% Average Percentage of Correct Keypoint (A-PCK) on TAP-Vid-Kinectics. Demos are available at this $\href{https://wkbian.github.io/Projects/Context-TAP/}{webpage}$.Comment: Project Page: this $\href{https://wkbian.github.io/Projects/Context-TAP/}{webpage}

Advances of the small molecule drugs regulating fibroblast-like synovial proliferation for rheumatoid arthritis

Rheumatoid arthritis (RA) is a type of chronic autoimmune and inflammatory disease. In the pathological process of RA, the alteration of fibroblast-like synoviocyte (FLS) and its related factors is the main influence in the clinic and fundamental research. In RA, FLS exhibits a uniquely aggressive phenotype, leading to synovial hyperplasia, destruction of the cartilage and bone, and a pro-inflammatory environment in the synovial tissue for perpetuation and progression. Evidently, it is a highly promising way to target the pathological function of FLS for new anti-RA drugs. Based on this, we summed up the pathological mechanism of RA-FLS and reviewed the recent progress of small molecule drugs, including the synthetic small molecule compounds and natural products targeting RA-FLS. In the end, there were some views for further action. Compared with MAPK and NF-κB signaling pathways, the JAK/STAT signaling pathway has great potential for research as targets. A small number of synthetic small molecule compounds have entered the clinic to treat RA and are often used in combination with other drugs. Meanwhile, most natural products are currently in the experimental stage, not the clinical trial stage, such as triptolide. There is an urgent need to unremittingly develop new agents for RA

Molecular engineering tuning optoelectronic properties of thieno[3,2-b]thiophenes-based electrochromic polymers

Thieno[3,2-b]thiophene (TT) monomers end-capped with 3,4-ethylenedioxythiophene (EDOT) moieties are electropolymerized to form pi-conjugated polymers with distinct electrochromic (EC) properties. Steric and electronic factors (electron donor and acceptor substituents) in the side groups of the TT core, as well as the structure of the polymer backbone strongly affect the electrochemical and optical properties of the polymers and their electrochromic characteristics. The studied polymers show low oxidation potentials, tunable from-0.78 to +0.30 V (vs. Fc/Fc(+)) and the band gaps from 1.46 to 1.92 eV and demonstrate wide variety of color palettes in polymer films in different states, finely tunable by structural variations in the polymer backbone and the side chains. EC materials of different colors in their doped/dedoped states have been developed (violet, deep blue, light blue, green, brown, purple-red, pinkish-red, orange-red, light gray, cyan and colorless transparent). High optical contrast (up to 79%), short response time (0.57-0.80 s), good cycling stability (up to 91% at 2000 cycles) and high coloration efficiency (up to 234.6 cm(2) C-1) have been demonstrated and the influence of different factors on the above parameters of EC polymers have been discussed.Shenzhen Key Laboratory of Organic Optoelectromagnetic Functional Materials of Shenzhen Science and Technology Plan [ZDSYS20140509094114164]; Shenzhen Peacock Program [KQTD2014062714543296]; Shenzhen Science and Technology Research Grant [JCYJ20140509093817690]; Nanshan Innovation Agency Grant [KC2015ZDYF0016A]; Guangdong Key Research Project [2014B090914003, 2015B090914002]; Guangdong Talents Project; National Basic Research Program of China [2015CB856505]; National Natural Science Foundation of China [51373075]; Guangdong Academician Workstation [2013B090400016]; Natural Science Foundation of Guangdong Province [2014A030313800]; Santander Universities Research Mobility AwardSCI(E)中国科学引文数据库(CSCD)ARTICLE163-766

Safety and tolerability of a single dose T0001 in Chinese healthy adult volunteers: a first-in-human ascending dose study

T0001 is the first mutant of etanercept with a higher affinity to tumor necrosis factor α (TNF-α) than etanercept. In order to investigate the safety and tolerability of T0001, a study was carried out in healthy Chinese subjects. A first-in-human, dose escalation study was conducted in healthy Chinese subjects. Fifty-six subjects were divided into six dose cohorts (10 mg, 20 mg, 35 mg, 50 mg, 65 mg and 75 mg) to receive a single subcutaneous injection of T0001. Safety and tolerability assessment were based on the records of vital signs, physical examinations, clinical laboratory tests, 12-lead electrocardiograms and adverse events (AEs). All subjects were in good compliance and none withdraw due to AEs. No serious AEs occurred. A total of twenty-three AEs in sixteen subjects were recorded, and eighteen of these AEs were believed to be related to T0001. The most frequently reported AEs were injection site reactions and white blood cell count increase. All these AEs were of mild to moderate intensity and most of them recovered spontaneously within 14 days. In this study, no dose-limiting toxicity was observed, and the maximum tolerated dose was identified as 75 mg. T0001 was considered safe and generally well tolerated at doses up to 75 mg in healthy Chinese volunteers

Updating systematic reviews can improve the precision of outcomes: a comparative study

Objectives: The objective of this study was to investigate the main characteristics and the precision of outcomes between updated and original systematic reviews (SRs). Study Design and Setting: We searched PubMed and Embase.com on 31 March 2019 and included 30 pairs of updated and original SRs. We calculated changes in outcomes and the precision of effect size estimates in updated SRs, compared with original SRs. Review Manager 5.3 software was adopted to create forest plots showing comparable outcomes. Results: The average update time was 56.0 months, and incorporating new trials (23 SRs, 76.7%) was the main reason for the update. Compared with original SRs, 24 (80.0%) updated SRs included more randomized controlled trials and 22 (73.3%) updated SRs involved a larger number of patients. Of the 130 comparable outcomes, only three (2.3%) outcomes were observed with a significant change in three SR updates. No new data from randomized controlled trials were added to 36 (27.7%) outcomes during the update process. Of the 94 outcomes including new evidence, 83 (88.3%) showed an improvement in precision, 5 (5.3%) showed a decrease in precision, and 6 (6.4%) did not exhibit changes in precision. Conclusion: Updating SRs could increase the precision of most comparable outcomes, although the conclusions of almost all updated SRs were similar to original SRs